Chordia --- significantly dropped, development halted for the inhibitor of the mucosal-associated lymphoid tissue lymphoma translocation protein 1.

Significantly declined. It has been announced that the strategic licensing partner, Ono Pharmaceutical Co., Ltd. <4528>, has decided to cease the development of the Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitor "CTX-177" for strategic reasons and return the rights related to its development, manufacturing, and commercialization to Chordia Therapeutics. Going forward, discussions will be held with Ono Pharmaceutical regarding the termination of the licensing agreement, and options will be considered.

Fisco Japan00:59 ET

Stocks hitting the upper and lower limits before the market.

■ Limit up <4240> Cluster Technology <4506> Sumitomo Pharma ■ Limit down <6836> Plat Home *Includes temporary limit up and down (indicative prices).

Fisco Japan23:24 ET

Sumitomo Pharma --- reached the upper limit of price increase, significantly revised upwards beyond expectations, making an impact.

The stock reached its upper limit. The upward revision of the financial results for the fiscal year ending in March 2025 was announced the day before yesterday. The core operating profit was raised from the previous estimate of 30 billion yen to 43.2 billion yen, while the previous term had a loss of 133 billion yen. In the North America segment, the treatment for advanced prostate cancer "Orgovix" appears to be exceeding expectations. Although impairment losses will be recognized, the operating profit has also been raised from 21 billion yen to 28.8 billion yen, significantly exceeding the market consensus of approximately 15 billion yen.

Fisco Japan21:23 ET

April 30 [Today's Investment Strategy]

[FISCO Selected Stocks]【Material Stocks】Komatsu Wall Industry <7949> 1480 yen (4/28) Engaged in office partitions and other products. Announced the financial results for the fiscal year ending March 2025. Operating profit was 3.635 billion yen (a 0.1% decrease from the previous period). The operating profit for the fiscal year ending March 2026 is projected at 4.06 billion yen (an 11.7% increase from the previous period). A Global Strategy review team has been established to plan and run growth strategies, including M&A. At the same time, a change in the shareholder return policy was announced, aiming for a dividend payout ratio (DOE) of 6%.

Fisco Japan20:06 ET

Stable, U.S. stocks are resilient and the buying intent continues.

[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a solid performance. The Dow Inc average rose by 114.09 dollars (+0.28%) in the US stock market two days ago on the 28th. Expectations for tax cuts and a stable bond market supported stock prices, while uncertainties regarding tariffs and the decline of NVIDIA (NVDA) weighed on them. Yesterday, on the 29th, it increased by 300.03 dollars (+0.75%) to 40,527.62 dollars, marking a sixth consecutive rise. Treasury Secretary Yellen stated that trade negotiations are progressing.

Fisco Japan19:20 ET

Pay attention to Komatsu Wall and Sumitomo Pharma, while Hokuriku Electric Industry and Hokuriku Electrical Utilities may be sluggish.

The day before yesterday, on the 28th, the Dow Jones Industrial Average in the U.S. stock market rose by $114.09, while the Nasdaq Composite Index fell by 16.81 points. Yesterday, on the 29th, the Dow Jones Industrial Average rose by $300.03 to 40,527.62, and the Nasdaq Composite Index rose by 95.19 points to 17,461.32. The Chicago Nikkei 225 Futures rose by 175 yen compared to Osaka's day session, reaching 36,085 yen. The exchange rate is 1 dollar = 142.20-30 yen. Today in the Tokyo market, Sumitomo Pharma ＜4506＞, which revised its earnings forecast upward for the fiscal year ending in March 2025.

Fisco Japan19:15 ET